Additional Data file 2:

Table S2. Substrate drugs with different affinities for either ABCB1 and/or ABCG2 were selected based on literature data. Similarly, their potencies to inhibit these transporters were also taken from literature reports. In all case, the concentrations used in the accumulation studies were far below the IC_{50} for either transporter.

Affinity of substrates for transport by ABCB1 and ABCG2					**Potency to inhibit ABCB1 and ABCG2**			
Reported substrate affinity	**Substrate drug**	**Affinity ABCB1**	**Affinity ABCG2**	**Reference**	**Cell line overexpressing ABCB1/ABCG2**	**IC_{50} ABCB1** (μM)	**IC_{50} ABCG2** (μM)	**Reference**
P-gp only substrate	Loperamide	+	-	[1]	-	NR	NR	-
	Verapamil	+	-	[2]	MDCK-MDR1 MDCK-BCRP	6.9	 137.8	[3]
Moderate dual substrate	Ibrutinib	+	+	[4]	KB-C2 K562/AO2 HEK393-ABCB1	1 .0 >2.5 >2.5	NR	[5]
	Erlotinib	+	+	[6]	KB-C2 HEK293-ABCG2	10	 2.5	[6]
	Palbociclib	+	+	[7]	KB-C2	3	NR	[8]
	Dasatinib	+	+	[9]	HEK293-ABCB1 HEK293-ABCG2	>10	 >10	[10]
Strong dual substrate	Vemurafenib	+	+	[11]	HEK293-ABCB1 H460/MX-20 HEK293MDR19 MCF7-FLV1000 MCF7-AdVp3000 S1-M1-80	>20 >50	 >20 1.24 4.91 2.60	[12, 13]
	Afatinib	+	+	[14]	A2780T H460/MX20 HEK293-ABCG2	2	 >1 0.5	[15, 16]

NR= not reported

Supplemental references to Table S2

1. Schinkel, A.H., et al., *P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.* J Clin Invest, 1996. **97**(11): p. 2517-24.
2. Bauer, M., et al., *Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study.* J Cereb Blood Flow Metab, 2015. **35**(5): p. 743-6.
3. Jacqueroux, E., et al., *Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.* Eur J Pharm Biopharm, 2020. **148**: p. 27-37.

4. van Hoppe, S., et al., *P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.* Mol Pharm, 2018. **15**(11): p. 5124-5134.
5. Zhang, H., et al., *The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.* Mol Cancer Ther, 2017. **16**(6): p. 1021-1030.
6. Shi, Z., et al., *Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.* Cancer Res, 2007. **67**(22): p. 11012-20.
7. Parrish, K.E., et al., *Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.* J Pharmacol Exp Ther, 2015. **355**(2): p. 264-71.
8. Fu, H., et al., *The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter.* Front Pharmacol, 2022. **13**: p. 861642.
9. Chen, Y., et al., *P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.* J Pharmacol Exp Ther, 2009. **330**(3): p. 956-63.
10. Dohse, M., et al., *Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.* Drug Metab Dispos, 2010. **38**(8): p. 1371-80.
11. Mittapalli, R.K., et al., *Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).* J Pharmacol Exp Ther, 2012. **342**(1): p. 33-40.
12. Vispute, S., et al., *Vemurafenib (PL4032, Zelboraf), a BRAF inhibitor, modulates ABCB1-, ABCG2-, and ABCC10-mediated multidrug resistance.* J. Cancer Res. Updates, 2013. **2**: p. 306-317.
13. Wu, C.P., et al., *Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.* Biochem Pharmacol, 2013. **85**(3): p. 325-34.
14. van Hoppe, S., et al., *Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.* Pharmacol Res, 2017. **120**: p. 43-50.
15. Wang, S.Q., et al., *Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.* Oncotarget, 2015. **6**(28): p. 26142-60.
16. Wang, X.K., et al., *Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.* Oncotarget, 2014. **5**(23): p. 11971-85.

Figure S2. **Accumulation of drugs in MDCKII parent, MDCK-MDR1 and MDCK-BCRP cells** We used an 8-drug mixture (loperamide, verapamil, erlotinib, vemurafenib, palbociclib, ibrutinib, dasatinib and afatinib), each at 100 nM, in combination with increasing concentrations of elacridar or tariquidar. Nonlinear curves were fitted using Graphpad. Unsuccessful fitting (no line) indicates that the compound is not transported by the respective ABC transporter. The drugs are classified as: (I) Abcb1 only substrates, (II) Abcb1 and weak Abcg2 substrates and (III) Abcb1 and strong Abcg2 substrates, as shown below. The inhibitor concentration *vs* intracellular drug level concentrations were fitted using the [Agonist] vs response –Variable slope (four parameters) nonlinear fit in Graphpad Prism 10.1.2. The dashed lines indicate the 90% CI.



Figure S2 (continued)

Class II

Erlotinib





Palbociclib





Dasatinib





Figure 2 (continued)